Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

HLA-DQ antibodies in alloimmunity, what makes them different?

  • Meneghini, Maria
  • Tambur, Anat
Anticossos; Aloimmunitat, Anticuerpos; Aloinmunidad, Antibodies; Alloimmunity, Purpose of review De novo HLA-DQ antibodies are the most frequently observed after solid-organ allotransplantation; and are associated with the worse adverse graft outcomes compared with all other HLA antibodies. However, the biological explanation for this observation is not yet known. Herein, we examine unique characteristics of alloimmunity directed specifically against HLA-DQ molecules. Recent findings While investigators attempted to decipher functional properties of HLA class II antigens that may explain their immunogenicity and pathogenicity, most early studies focused on the more expressed molecule – HLA-DR. We here summarize up-to-date literature documenting specific features of HLA-DQ, as compared to other class II HLA antigens. Structural and cell-surface expression differences have been noted on various cell types. Some evidence suggests variations in antigen-presenting function and intracellular activation pathways after antigen/antibody interaction. Summary The clinical effects of donor-recipient incompatibility at HLA-DQ, the risk of generating de novo antibodies leading to rejection, and the inferior graft outcomes indicate increased immunogenicity and pathogenicity that is unique to this HLA antigen. Clearly, knowledge generated for HLA-DR cannot be applied interchangeably. Deeper understanding of features unique to HLA-DQ may support the generation of targeted preventive-therapeutic strategies and ultimately improve solid-organ transplant outcomes., M.M. has been supported by the program Estades formatives internacionals en centres d’excel.lència Hospital Universitari Vall d’Hebron (convocatòria 2022); Instituto de Salud Carlos III (ISCIII) (grant number PI22/00749) and the RICORS (Redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia by the Instituto de Salud Carlos III. A.R.T. is a Paul I Terasaki scholar and received funding from the Michael Abecassis Transplant Innovation Endowment/Northwestern University Comprehensive Transplant Program.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

HLA-DQ antibodies in alloimmunity, what makes them different?

  • Meneghini, Maria
  • Tambur, Anat
Anticossos; Aloimmunitat, Anticuerpos; Aloinmunidad, Antibodies; Alloimmunity, Purpose of review De novo HLA-DQ antibodies are the most frequently observed after solid-organ allotransplantation; and are associated with the worse adverse graft outcomes compared with all other HLA antibodies. However, the biological explanation for this observation is not yet known. Herein, we examine unique characteristics of alloimmunity directed specifically against HLA-DQ molecules. Recent findings While investigators attempted to decipher functional properties of HLA class II antigens that may explain their immunogenicity and pathogenicity, most early studies focused on the more expressed molecule – HLA-DR. We here summarize up-to-date literature documenting specific features of HLA-DQ, as compared to other class II HLA antigens. Structural and cell-surface expression differences have been noted on various cell types. Some evidence suggests variations in antigen-presenting function and intracellular activation pathways after antigen/antibody interaction. Summary The clinical effects of donor-recipient incompatibility at HLA-DQ, the risk of generating de novo antibodies leading to rejection, and the inferior graft outcomes indicate increased immunogenicity and pathogenicity that is unique to this HLA antigen. Clearly, knowledge generated for HLA-DR cannot be applied interchangeably. Deeper understanding of features unique to HLA-DQ may support the generation of targeted preventive-therapeutic strategies and ultimately improve solid-organ transplant outcomes., M.M. has been supported by the program Estades formatives internacionals en centres d’excel.lència Hospital Universitari Vall d’Hebron (convocatòria 2022); Instituto de Salud Carlos III (ISCIII) (grant number PI22/00749) and the RICORS (Redes de Investigación Cooperativa Orientadas a Resultados en Salud) consortia by the Instituto de Salud Carlos III. A.R.T. is a Paul I Terasaki scholar and received funding from the Michael Abecassis Transplant Innovation Endowment/Northwestern University Comprehensive Transplant Program.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

On the relative relevance of donor-derived cell-free DNA and urinary chemokines as noninvasive biomarkers for the diagnosis of kidney allograft rejection

  • Carrera Muñoz, Claudia
  • Font Miñarro, Cristina
  • Juvé Torres, Mariona
  • Castañeda Amado, Zaira Ivette
  • Torres, Irina B.
  • Casanova, Franc
  • Gabaldon, Maria Alejandra
  • Alvarez, Tiffany
  • Cantenys, Sergi
  • KERVELLA, Delphine
  • Meneghini, Maria
  • Crespo, Elena
  • Zamora Carrillo, Jorge Ivan
  • Patricio-Liébana, Marc
  • Sellarès , Joana
  • Perelló, Manel
  • Martínez Gallo, Mónica
  • Moreso, Francesc
  • Bestard, Oriol
Biomarkers; Donor-derived cell-free DNA; Rejection, Biomarcadores; ADN libre de células derivado de donantes; Rechazo, Biomarcadors; ADN lliure de cèl·lules derivat de donants; Rebuig, Donor-derived cell-free deoxyribonucleic acid (DNA) (dd-cfDNA) and urinary chemokines are promising noninvasive biomarkers for kidney allograft rejection, but direct comparative data are lacking. In this prospective pilot study, we analyzed 194 biopsies (101 for-cause, 93 surveillance) paired with dd-cfDNA and urinary chemokine (CXCL9, CXCL10, CCL2, VEGF-A) concentrations in kidney transplant recipients. We evaluated their correlation, diagnostic accuracy for rejection phenotypes, and integration into diagnostic models with clinical and immunologic variables. Rejection was diagnosed in 32.5% of biopsies, predominantly antibody-mediated. dd-cfDNA showed strong diagnostic performance in both for-cause (area under the receiver operating characteristic curve [AUC] 0.85) and surveillance (AUC 0.91) biopsies. Conversely, urinary chemokines, particularly the composite Score4, showed accuracy mainly in for-cause biopsies (AUC 0.76). Remarkably, Score4 combined with donor-specific antibodies showed similar performance as dd-cfDNA + donor-specific antibodies (AUC 0.90) in for-cause biopsies. Internal bootstrap validation, including calibration metrics, confirmed the consistency of the models. dd-cfDNA provides robust diagnostic accuracy for kidney allograft rejection across distinct clinical settings. Urinary chemokine measures, especially Score4, may offer valuable diagnostic utility in for-cause biopsies. These findings support context-specific integration of noninvasive biomarkers and represent the first direct comparison of dd-cfDNA and urinary chemokines, informing personalized approaches to rejection monitoring., The results reported in this manuscript were supported by competitive research grants from the Instituto de Salud Carlos III (isciii) PI18/01832, PI23/01909, PI22/00749, PI22/01019, RICORS2040-Renal (Redes de Investigación Cooperativa Orientadas a Resultados en Salud financed by Instituto Salud Carlos III and cofinanced by the European Union (O.B.), RD21/0005/0016) and European Union (ERDF/ESF)-A way to build Europe (O.B.).